Bavarian Nordic's IMVAMUNE(R) Smallpox Vaccine Highlighted as Success Story in WMD Center's Bio-Response Report Card

Bavarian Nordic

13.10.2011 14:37 ---------------------------------------------------------------------------

KVISTGARD, Denmark, 2011-10-13 14:37 CEST (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (Copenhagan:BAVA) today applauded the release of the WMD Center's Bio-Response Report Card, which concluded that the response to the threat of smallpox is one of the top success stories for biodefense during the past decade. The bipartisan Report Card highlights the winning public-private partnership between Bavarian Nordic and the U.S. Government on the development of IMVAMUNE(r), a non-replicating smallpox vaccine.

'We are proud that the experts at the WMD Center believe that our partnership with the U.S. government is a biodefense success story,' said Bavarian Nordic President and CEO Anders Hedegaard. 'In addition to biodefense, we also have a strong public-private partnership with the National Cancer Institute. We look forward to maintaining and growing these partnerships to combat bioterrorism and advance public health.'

IMVAMUNE(r) is the first vaccine successfully developed under Project BioShield, a program created by Congress in 2004 to develop and purchase medicines and vaccines to protect the American public from bioterrorism attacks. Despite its eradication, bioterrorism experts are concerned about the possibility of an attack on the U.S. that exposes the population to the smallpox virus.

In 2011, Bavarian Nordic expects to deliver 4 million doses of the vaccine to the U.S. Strategic National Stockpile, bringing the total inventory to over 6 million doses. Under the BARDA contract, the company will deliver 20 million doses of IMVAMUNE(r), with an option for 60 million more doses.

According to the report: 'The development of smallpox vaccine suitable for immune compromised individuals is a textbook example of how the system should work. NIH funded both the basic and applied science and then transitioned the program to BARDA, which funded advanced development and procurement. This generation III smallpox vaccine is now in the Strategic National Stockpile (SNS) and available for use during an emergency.'

About Bavarian Nordic

Bavarian Nordic is a leader in the development and production of novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's clinical pipeline targets cancer and infectious diseases, and includes seven development programs. Two programs are

under preparation for Phase III: IMVAMUNE(r), a third-generation smallpox vaccine

that is being developed under a contract with the US government, and PROSTVAC(r),

a treatment for advanced prostate cancer that is being developed under a collaboration agreement with the National Cancer Institute.

For more information, visit www.bavarian-nordic.com

About the WMD Center and Report Card

The WMD Center is a not-for-profit 501(c)(3) research and education organization founded in March 2010 by the chair, vice chair, and executive director of the Congressional Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism. The WMD Center's Bio-Response Report Card provides an objective, peer-reviewed, strategic assessment of the U.S. bio-response enterprise, and offers policy recommendations in seven key areas of bio-response.

For more information, and to access the Report Card, visit www.wmdcenter.org

Forward-looking statements

This announcement includes 'forward-looking statements' that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

CONTACT: Paul Chaplin, Division President, Infectious Diseases, Bavarian Nordic Phone 202-288-9220 News Source: NASDAQ OMX

13.10.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de

--------------------------------------------------------------------------- Language: English Company: Bavarian Nordic Dänemark Phone: Fax: E-mail: Internet: ISIN: DK0015998017 (BAVARIAN NORDIC Aktie) WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------